Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ist + hetrombopag
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**ist + hetrombopag** refers to the combination of **immunosuppressive therapy (IST)**, typically consisting of antithymocyte globulin (ATG) and cyclosporine, with **hetrombopag**, an oral, small molecule, synthetic, nonpeptide thrombopoietin receptor agonist (TPO-RA). This combination is primarily used as a first-line regimen or for refractory cases in patients with **severe aplastic anemia (SAA)** who are ineligible for hematopoietic stem cell transplantation (HSCT). Hetrombopag binds to the transmembrane domain of the thrombopoietin (TPO) receptor (encoded by the MPL gene), stimulating platelet production and hematopoiesis. Clinical studies indicate that adding hetrombopag to IST increases hematologic response rates, shortens time to response, and improves transfusion independence compared with IST alone, without significant new safety concerns. The combination is also under investigation for other thrombocytopenic disorders[1][3][6].
- Brand names
- HengquThymoglobulinNeoralSandimmune
- Other names
- ist + hetrombopag
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on ist + hetrombopag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ist + hetrombopag.